Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 9/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340683 | 0.92 | GABRA1 (0.37) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL7987422 | 0.89 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6772522 | 0.87 | GABRG2 (0.38) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL341136 | 0.85 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL339264 | 0.84 | GABRA1 (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6990798 | 0.84 | GABRA1 (0.42) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL6773755 | 0.84 | GABRG2 (0.34) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL2646459 | 0.83 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL340433 | 0.83 | KDM4E (0.40) | HSD17B10KDM4EHPGDDPP4ALOX15 | |
| SCHEMBL2646918 | 0.82 | GABRG2 (0.55) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0915875-B1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2003-04-09 | — | — | EP | claimed |
| US-6174886-B1 | TREATMENT AND/OR PREVENTION OF PSYCHOTIC DISORDERS INCLUDING SCHIZOPHRENIA WITH REDUCED SEDATION; SELECTIVE LIGANDS FOR GAMMA-AMINOBUTYRIC ACID A RECEPTORS, IN PARTICULAR HAVING HIGH AFFINITY FOR THE ALPHA2 AND/OR ALPHA3 SUBUNIT | MERCK SHARP & DOHME LTD. (GB) | 2001-01-16 | — | — | US | claimed |
| US-6063783-A | Analgesic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-05-16 | — | — | US | claimed |
| US-6046196-A | Antispastic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-04-04 | — | — | US | claimed |
| WO-1999025353-A1 | THERAPEUTIC USES OF TRIAZOLO-PYRIDAZINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-05-27 | — | — | WO | claimed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | claimed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | claimed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8097625-B2 | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | SUNOVION PHARMACEUTICALS INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2343073-A2 | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | Sepracor Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20050215521-A1 | Modafinil combination therapy for improving sleep quality | SEPRACOR INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | SEPRACOR, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-6110915-A | Antiemetic use of triazolo-pyridazine derivatives | MERCK & CO., INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6107296-A | Neuroprotective use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 2000-08-22 | — | — | US | disclosed |
| US-6063783-A | Analgesic use of triazolo-pyridazine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-05-16 | — | — | US | disclosed |
| WO-1999037303-A1 | COMBINATION OF A GABA-A ALPHA 2/3 AGONIST AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR | MERCK SHARP & DOHME LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999025353-A1 | THERAPEUTIC USES OF TRIAZOLO-PYRIDAZINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-05-27 | — | — | WO | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | GABRA1 54/4885GABRG2 94/4885GABRB3 100/4885 |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | HTR2A, HTR2C, HTR5A | GABRA1 76/4885GABRG2 167/4885GABRB3 133/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | GABRA1 46/4885GABRG2 97/4885GABRB3 85/4885 |
| US-20050215521-A1 | Modafinil combination therapy for improving sleep quality | HCRTR2, HCRTR1, MTNR1A | GABRA1 220/4885GABRG2 478/4885GABRB3 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.